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Supplementary Table 1. Study subject characteristics used in the study. 
Cohort Subjects number Age 
(median, range) 
Sex 
(male/female) 
HLA DR3/x 
n (%) 
HLA DR4/x 
n (%) 
1 Controls 200 11 years, 6-18 110/90 - - 
1 Patients 500* 10 years, 1-19 278/222 87(42.6%) 144 (70.6%) 
2 Patients 751** 10 years, 1-20 414/337 302(40.2%) 501(66.7%) 
*HLA DR data was available in 204 of these patients 
**Only 740 of these had sufficient sample remaining to measure anti-MLH1 
 
 
Supplementary Table 2. Antibody combinations in patients and controls from cohort 1 
Positive antibody combinations Patients with type 1 diabetes 
N=500 
Controls 
N=200 
MTIF3, PPIL2, NUP50, MLH1 1 (0.2%) 0 
MTIF3, PPIL2, NUP50 4 (0.8%) 0 
MTIF3, PPIL2, MLH1 3 (0.6%) 0 
MTIF3, NUP50, MLH1 2 (0.4%) 0 
PPIL2, NUP50, MLH1 0 0 
MTIF3, PPIL2 3 (0.6%) 0 
MTIF3, NUP50 2 (0.4%) 1 (0.5%) 
MTIF3, MLH1 3 (0.6%) 0 
PPIL2, NUP50  7 (1.4%) 1 (0.5%) 
PPIL2, MLH1 3 (0.6%) 0 
NUP50, MLH1 4(0.8%) 0 
MTIF3 only 103 (20.6%) 4 (2%) 
PPIL2 only 14 (2.8%) 4 (2%) 
NUP50 only 9 (1.8%) 3 (1.5%) 
MLH1 only 21 (4.2%) 5 (2.5%) 
 
 
